Preferred Label : Dabrafenib/Trametinib Regimen;
NCIt synonyms : Dabrafenib-Trametinib Regimen; Dabrafenib Plus Trametinib; Dabrafenib/Trametinib; Dabrafenib Trametinib; Tafinlar/Mekinist; Tafinlar-Mekinist;
NCIt related terms : Dabrafenib and Trametinib;
NCIt definition : A regimen consisting of dabrafenib and trametinib that can be used in the treatment
of certain BRAF-mutated cutaneous melanomas, non-small cell lung cancers (NSCLCs),
anaplastic carcinoma, central nervous system (CNS) cancers, gastric, esophageal and
esophagogastric junction cancers, salivary gland tumors, oncocytic carcinoma, ovarian,
fallopian tube and primary peritoneal cancers, follicular, papillary and Hurthle cell
thyroid carcinomas, ampullary, pancreatic and small bowel adenocarcinoma, gallbladder
or cholangiocarcinoma, gastrointestinal stromal tumor (GIST), occult primary adenocarcinoma
or squamous cell carcinoma, extrapulmonary poorly differentiated neuroendocrine carcinoma,
large or small cell carcinoma, and mixed neuroendocrine-non-neuroendocrine neoplasm.;
NCI Metathesaurus CUI : CL555216;
Codes from synonyms : 5134;
Origin ID : C154325;
UMLS CUI : C4727581;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib
---
https://www.ema.europa.eu/en/medicines/human/EPAR/finlee
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dabrafenib
dabrafenib
dabrafenib
drug approval
orphan drug production
glioma
malignant glioma
infant
child
antineoplastic combined chemotherapy protocols
Dabrafenib/Trametinib Regimen
Childhood Low Grade Glioma
Childhood Malignant Glioma
europe
Dabrafenib Mesylate
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
BRAF V600E Mutation Present
administration, oral
BRAF Inhibitor
proto-oncogene proteins b-raf
drug interactions
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/spexotras
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
trametinib
trametinib
antineoplastic agents
protein kinase inhibitors
administration, oral
drug approval
Trametinib Dimethyl Sulfoxide
orphan drug production
infant
child
europe
trametinib
antineoplastic combined chemotherapy protocols
glioma
Dabrafenib/Trametinib Regimen
Childhood Malignant Glioma
Childhood Low Grade Glioma
malignant glioma
glioma
BRAF V600E Mutation Present
Mitogen-Activated Protein Kinase Kinase Inhibitor
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3450970/en/dabrafenib-trametinib-novartis-dabrafenib-trametinib-gliome-pediatrie
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infant
child
malignant glioma
BRAF V600E Mutation Present
Low Grade Glioma
administration, oral
dabrafenib
trametinib
protein kinase inhibitors
antineoplastic agents
guidelines for drug use
Dabrafenib/Trametinib Regimen
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
trametinib
dabrafenib
glioma
---
